Category: New research findings

There are now two anti-amyloid monoclonal antibodies that appear to be effective in slowing the progression of cognitive impairment in people with mild Alzheimer’s disease. The benefit may be small, 27% for lecanemab and...

Yesterday Eli Lilly issued a press release summarizing positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slows cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Donanemab is unique...

Early in my career as a neurologist, probably about 1990, I was asked to consult on a 62-year-old, previously healthy woman who had had a large brain hemorrhage. She had no apparent risk factors...

Over the last ten years or so, I have noticed increasing trouble understanding what people are saying to me, especially if there are several people speaking at the same time, like at a family...

Early in my career as a general neurologist, there was no way to accurately make a diagnosis of Alzheimer’s disease in a living patient. The only way then to know for sure that a...

Today the FDA granted accelerated approval of the anti-amyloid monoclonal antibody lecanemab, now going by the trade name Leqembi. I have mixed feelings about this. Lecanemab is the only disease-modifying drug so far to...

My friend Ron Louie is a pediatric oncologist and fulltime caregiver for his wife who has Alzheimer’s disease. He blogs regularly, often drawing intriguing comparisons of the search for an effective treatment for Alzheimer’s...

At some point while I was a medical student in the 1970s, I had my cholesterol checked. I think it was part of a pedagogical exercise, and as I recall, only the total cholesterol...